NYSE · EVAC.WS

EQV Ventures Acquisition Corp.. II Redeemable , each whole exercisable for one at an exercise price of $11. 50 per

$0.36 +$0.01 (+4.41%) 1D

Key Metrics

Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 0.77
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 10
    The stock moved +13.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 10
  • Apr 15
    The stock moved +27.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 15
  • Apr 14
    From its Jan 30 high, the share price fell 38%.

    Peak close $0.48 on Jan 30; trough close $0.30 on Apr 14. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.22 – $0.51
Avg volume · 20D37.6K
Net cash
Book value / share
IndustryBlank Checks
ExchangeNYSE
About EQV Ventures Acquisition Corp.. II Redeemable , each whole exercisable for one at an exercise price of $11. 50 per
IPO dateAug 22, 2025
Employees

EQV Ventures Acquisition Corp II is a blank check company.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio5.95
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.31M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings